Turkish Abstract Abstract Article PDF Similar Articles Mail to Author

¹M.D., Karaman State Hospital Eye Clinic, Karaman/TURKEY
²Bakırköy Training and Research Hospital, Eye Clinic, İstanbul/TURKEY Purpose: To evaluate the results of intravitreal Ranibizumab injection in our own case series treatment with wet type age-related macular degeneration (AMD).
Materials and Methods: Thirty-five eyes of 31 patients diagnosed with wet type AMD that had undergone intravitreal ranibizumab injection were included in this prospective study in our clinic. Eyes of patients older than 50, with best corrected visual acuity (BCVA) better than 1.3 logMAR according to the ETDRS acuity chart and in which there were no subfoveolar structural damage prior to treatment and choroidal neovascular membrane (CRNVM) of the greatest diameter below 5400 μm in fundus fluorescein angiography (FFA) related to diseases other than AMD, and IOP below 21 mmHg were included. Following three consecutive injections, re-injections were considered on the basis of FFA, BCVA, and OCT findings on monthly examinations. Eyes were assessed for central macular thickness (CMT), BCVA, number of injections, and side effects before and after.
Results: While 17 (54.8%) patients were female, 14 (45.2%) were male. Mean age was 73.03±8.59 (52-90 years). Mean follow-up time and number of injections were 10.14±3.59 (6-18 months) and 3.71±1.01 (3-7 injections) respectively. Of the eyes, 23 (65.7%) had classical and 12 (34.3%) had pure occult CRNVM. Seven eyes (20%) had undergone treatment prior to enrollment, while 28 patients (80%) did not undergo treatment. Before treatment, median BCVA was 0.82 logMAR; after treatment it was 0.62. Mean CMT was 386.05 μm before and 315.65 μm after treatment.
Conclusion: Intravitreal ranibizumab provides functional and anatomical benefits in wet type AMD. Keywords : Age-related macular degeneration, ranibizumab, vascular endothelial growth factor